Lichen planus (LP) is a T-cell-mediated chronic inflammatory condition affecting the skin, mucous membranes, hair, and nails. Conventional therapies include corticosteroids and immunosuppressants, but data are lacking on therapy recommendations for patients with LP who do not respond to first-line treatments. We performed a literature review to investigate the off-label use of adalimumab for treatment of LP.